Market Trends of Europe Bladder Cancer Therapeutics and Diagnostics Industry
Immunotherapy Segment is Expected to Show Better Growth in the Forecast period.
- Immunotherapy is a therapy that uses drugs to suppress or stimulate the immune system to help the body fight against bladder cancer. It relates to biological therapy for cancer treatment to boost the body's natural defenses to fight cancer. The advantages of immunotherapy over chemotherapy in a bladder cancer patient and product launches by the key market players drive the segment.
- For instance, according to an article published by Health Union, LLC, in February 2023, immunotherapies alert and train a person's immune system to identify and destroy cancer cells. Immunotherapy continues working even after the treatment period ends. In contrast, chemotherapy kills cancer and healthy cells while the drugs are in a person's body. The advantage of immunotherapy over chemotherapy is expected to drive the segment demand over the forecast period.
- Various strategies adopted by the key market players support the market growth over the forecast period. For instance, in January 2021, the European Commission approved nivolumab (Bavencio) as a frontline maintenance option in treating adult patients with locally advanced or metastatic urothelial carcinoma who did not progress after having received platinum-based chemotherapy.
- Avelumab is the immunotherapy to demonstrate a significant improvement in overall survival in the setting in a phase 3 study in advanced or metastatic bladder cancer. Thus, all factors above are expected to post the segment growth over the forecast period.
Understand The Key Trends Shaping This Market
Download Sample
Germany is Expected to Hold a Significant Share of the Market Over the Forecast Period
- Germany holds a significant share due to the rise in the burden of bladder cancer, the presence of many companies, and the tremendous growth of bladder cancer therapeutics and diagnostics in the region. For instance, according to an article published by Deutsches Ärzteblatt International in October 2021, bladder carcinomas account for 3-4% of all malignant tumors in Germany. They occur at the age peak over 70 years. Bladder cancer is the fourth most common tumor in men in Germany and 14th in women.
- Furthermore, according to an article published by Booking Health GmbH in November 2022, bladder cancer ranks fourth in Germany amongst other oncology cases. Moreover, in Germany, about 15,000 patients are diagnosed with bladder cancer annually, which urges German medicine to develop the bladder cancer field of oncology. Thus, the increasing burden of bladder cancer due to the rise in the geriatric population in Germany is anticipated to increase the demand for bladder cancer therapeutics and diagnostics, thereby propelling the market growth.
- Additionally, various strategies adopted by the key market players support the market growth over the forecast period. For instance, in November 2022, Immutep Limited signed a Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for a new Phase I clinical study in patients with urothelial cancer called INSIGHT-005. Thus, all factors above are expected to boost the market growth in Germany over the forecast period.
Get Analysis on Important Geographic Markets
Download Sample
